Isometheptene mucate | 7492-31-1

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Isometheptene mucate
• 英文别名: N,6-dimethylhept-5-en-2-amine;(2S,3R,4S,5R)-2,3,4,5-tetrahydroxyhexanedioic acid
• CAS: 7492-31-1
• 化学式: C24H48N2O8
• 分子量: 492.6
• InChiKey: WSXKZIDINJKWPM-IBGZLQDMSA-N

物化性质

• 熔点：
  140-142°C
• 溶解度：
  可溶于DMSO（轻微加热）、甲醇（轻微超声处理）、水（少量）

计算性质

• 辛醇/水分配系数(LogP)：
  1.28
• 重原子数：
  34
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  180
• 氢给体数：
  8
• 氢受体数：
  10

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R40
• 安全说明：
  S22,S36

文献信息

• [EN] 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES 3,3-DIFLUOROPIPÉRIDINE CARBAMATE UTILISÉS EN TANT QU'ANTAGONISTES DES RÉCEPTEURS NMDA NR2B
  申请人：RUGEN HOLDINGS (CAYMAN) LTD

  公开号：WO2016196513A1

  公开（公告）日：2016-12-08

  Disclosed are chemical entities of Formula (I), wherein R1 and Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).

  本文披露了化学实体的化学式（I），其中R1和Z如本文所定义，作为NR2B亚型选择性受体拮抗剂。还披露了包括化学实体的化学式（I）的药物组合物，以及通过给予化学实体的化学式（I）来治疗与NR2B拮抗作用相关的各种疾病和疾病的方法，例如中枢神经系统疾病和疾病，如抑郁症。
• [EN] NOVEL (R)-ISOMETHEPTENE COMPOSITIONS AND USES<br/>[FR] NOUVELLES COMPOSITIONS DE (R)-ISOMETHEPTÈNE ET UTILISATIONS
  申请人：LEDERMAN SETH

  公开号：WO2015188005A1

  公开（公告）日：2015-12-10

  The invention relates to the preparation and characterization of novel salts of (R)-isometheptene and crystalline forms thereof; moreover, the invention describes the use of the novel salts alone or in combination with other therapeutic salts for treatment of various conditions, such as hypertension or a headache, or as a sedative.

  这项发明涉及(R)-异甲氢鼠尾草酮的新型盐的制备和表征，以及其晶体形式；此外，该发明描述了利用这些新型盐单独或与其他治疗盐结合治疗各种疾病的用途，如高血压或头痛，或作为镇静剂。
• Dendrimers as molecular translocators
  申请人：Goodman Murray

  公开号：US20060216265A1

  公开（公告）日：2006-09-28

  Transport molecules include a dendrimer and a biologically active molecule. The dendrimer of such transport molecules includes at least one guanidine group, at least one protonated guanidine group, at least one protected guanidine group, at least one amidine group, at least one protonated amidine group, at least one protected amidine group, at least one ureido group, at least one protonated ureido group, at least one protected ureido group, at least one thioureido group, at least one protonated thioureido group, or at least one protected thioureido group. The biologically active molecule is bonded to the dendrimer. A method of increasing the bioavailability of a drug includes bonding the drug to a dendrimer of the invention.

  转运分子包括一种树枝状聚合物和一种生物活性分子。这些转运分子的树枝状聚合物包括至少一个胍基团、至少一个质子化的胍基团、至少一个保护的胍基团、至少一个酰胺基团、至少一个质子化的酰胺基团、至少一个保护的酰胺基团、至少一个脲基团、至少一个质子化的脲基团、至少一个保护的脲基团、至少一个硫脲基团、至少一个质子化的硫脲基团，或至少一个保护的硫脲基团。生物活性分子与树枝状聚合物结合。一种增加药物生物利用度的方法包括将药物与本发明的树枝状聚合物结合。
• Non-Racemic Mixtures of Various Ratios of D- and L-methadone and Methods of Treating Pain Using the Same
  申请人：MIRONER Y. Eugene

  公开号：US20160235691A1

  公开（公告）日：2016-08-18

  Non-racemic mixtures of D- and L-methadone containing a ratio ranging from about 2.5:1 to about 3.5:1 by weight of D-methadone to L-methadone, such as for example about 2.9:1 to about 3.1:1 by weight of D-methadone to L-methadone, or about 3:1 by weight of D-methadone to L-methadone, have been found to exhibit surprising and unexpected beneficial results in the treatment of neuropathic pain. Additionally, non-racemic mixtures of D- and L-methadone containing a ratio ranging from about 2.5:1 to about 3.5:1 by weight of D-methadone to L-methadone, about 2.9:1 to about 3.1:1 by weight of D-methadone to L-methadone, or for example about 3:1 by weight of D-methadone to L-methadone, in combination with other non-methadone opioids have been found to exhibit surprising and unexpected beneficial results in the treatment of mixed pain.

  非外消旋混合物的D-和L-美沙酮，其含有D-美沙酮与L-美沙酮按重量比大约为2.5:1至大约3.5:1，例如大约为2.9:1至大约3.1:1，或者大约为3:1，已被发现在神经痛的治疗中表现出令人惊讶和意想不到的益处。此外，非外消旋混合物的D-和L-美沙酮，其含有D-美沙酮与L-美沙酮按重量比大约为2.5:1至大约3.5:1，大约为2.9:1至大约3.1:1，或者例如大约为3:1，与其他非美沙酮类阿片类药物结合使用，已被发现在混合性疼痛的治疗中表现出令人惊讶和意想不到的益处。
• [EN] IMIDAZOLINE RECEPTOR TYPE 1 LIGANDS FOR USE AS THERAPEUTICS<br/>[FR] LIGANDS DU RÉCEPTEUR AUX IMIDAZOLINES DE TYPE 1 À UTILISER EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：RIDEOUT DARRYL

  公开号：WO2016105448A1

  公开（公告）日：2016-06-30

  This disclosure provides compounds and compositions for use as analgesics and for the treatment of various conditions, such as pain, headaches, allodynia, and fibromyalgia. The disclosure also provides compounds that are ligands, and in some embodiments, modulators (e.g., agonists), for the imidazoline receptor type 1.

  本公开提供了作为止痛剂和用于治疗各种病症的化合物和组合物，如疼痛、头痛、触痛和纤维肌痛。本公开还提供了作为嘌呤受体1的配体的化合物，有些实施例中还提供了对其的调节剂（例如，激动剂）。